AAPL332.27+5.70 (+1.75%) ▲|ABBV257.12+2.12 (+0.83%) ▲|ABT104.20+2.20 (+2.15%) ▲|ACN192.45+8.59 (+4.67%) ▲|ADBE263.36+11.13 (+4.41%) ▲|AMAT421.84-34.65 (-7.59%) ▼|AMD484.37-31.76 (-6.15%) ▼|AMGN380.36+3.01 (+0.80%) ▲|AMT177.54-0.33 (-0.19%) ▼|AMZN254.39-2.40 (-0.93%) ▼|AVGO347.05-14.95 (-4.13%) ▼|AXP326.50+1.82 (+0.56%) ▲|BA209.55-0.78 (-0.37%) ▼|BAC62.35-0.34 (-0.53%) ▼|BKNG180.52+6.60 (+3.79%) ▲|BLK1,075.02-4.57 (-0.42%) ▼|BMY64.64+1.02 (+1.60%) ▲|BNY160.77-1.90 (-1.17%) ▼|BRK-B513.81+3.47 (+0.68%) ▲|C136.63-2.17 (-1.56%) ▼|CAT781.18-37.37 (-4.56%) ▼|CL88.32+1.54 (+1.77%) ▲|CMCSA25.34+0.14 (+0.56%) ▲|COF208.23-0.02 (-0.01%) ▼|COP139.12+1.75 (+1.27%) ▲|COST915.63+10.86 (+1.20%) ▲|CRM255.22+7.57 (+3.05%) ▲|CSCO110.03-2.10 (-1.87%) ▼|CVS95.72+1.05 (+1.11%) ▲|CVX216.90+2.86 (+1.34%) ▲|DE671.51-4.78 (-0.71%) ▼|DHR201.62+1.53 (+0.76%) ▲|DIS108.32+1.78 (+1.67%) ▲|DUK120.28+0.86 (+0.72%) ▲|EMR147.30-4.86 (-3.19%) ▼|FDX312.04+1.26 (+0.40%) ▲|GD357.16+1.25 (+0.35%) ▲|GE312.74-10.87 (-3.36%) ▼|GEV881.50-75.07 (-7.85%) ▼|GILD144.79+1.07 (+0.74%) ▲|GM86.44+0.82 (+0.96%) ▲|GOOG340.45+5.00 (+1.49%) ▲|GOOGL344.02+5.52 (+1.63%) ▲|GS1,008.54-20.57 (-2.00%) ▼|HD310.18+1.45 (+0.47%) ▲|HON199.13-3.23 (-1.60%) ▼|IBM246.04+2.80 (+1.15%) ▲|INTC95.43-7.51 (-7.30%) ▼|INTU339.11+17.54 (+5.45%) ▲|ISRG375.09+5.94 (+1.61%) ▲|JNJ269.57+3.95 (+1.49%) ▲|JPM353.51-2.77 (-0.78%) ▼|KO89.77+1.51 (+1.71%) ▲|LIN464.39-1.83 (-0.39%) ▼|LLY1,134.64+19.41 (+1.74%) ▲|LMT526.57+2.65 (+0.51%) ▲|LOW198.32+1.51 (+0.76%) ▲|LRCX274.44-23.79 (-7.98%) ▼|MA577.58+8.43 (+1.48%) ▲|MCD257.22+4.71 (+1.86%) ▲|MDLZ63.52+1.08 (+1.73%) ▲|MDT93.48+2.50 (+2.75%) ▲|META659.26+11.23 (+1.73%) ▲|MMM162.80-2.15 (-1.31%) ▼|MO70.96+1.99 (+2.89%) ▲|MRK145.72+1.78 (+1.24%) ▲|MS211.07-3.32 (-1.55%) ▼|MSFT496.53+0.90 (+0.18%) ▲|MU904.89-70.38 (-7.22%) ▼|NEE82.51+0.20 (+0.24%) ▲|NFLX79.77+2.37 (+3.06%) ▲|NKE37.12+0.30 (+0.82%) ▲|NOW140.94+8.41 (+6.34%) ▲|NVDA209.12-9.17 (-4.20%) ▼|ORCL141.79-8.36 (-5.57%) ▼|PEP138.52+2.20 (+1.61%) ▲|PFE27.95+0.26 (+0.94%) ▲|PG147.15+1.93 (+1.33%) ▲|PLTR167.08-0.15 (-0.09%) ▼|PM194.68+3.59 (+1.88%) ▲|QCOM176.50-5.48 (-3.01%) ▼|RTX195.71-1.97 (-1.00%) ▼|SBUX99.41+0.67 (+0.68%) ▲|SCHW107.49+0.24 (+0.22%) ▲|SO87.59+0.42 (+0.48%) ▲|SPG206.18+1.35 (+0.66%) ▲|T26.35+0.29 (+1.09%) ▲|TMO612.55+2.55 (+0.42%) ▲|TMUS185.25+2.92 (+1.60%) ▲|TSLA361.18-4.26 (-1.17%) ▼|TXN262.23-6.47 (-2.41%) ▼|UBER71.61-0.06 (-0.08%) ▼|UNH381.93+5.16 (+1.37%) ▲|UNP284.78+0.38 (+0.13%) ▲|UPS101.25+0.97 (+0.96%) ▲|USB62.98+0.14 (+0.22%) ▲|V375.96+5.51 (+1.49%) ▲|VZ51.13+0.52 (+1.03%) ▲|WFC90.13-0.16 (-0.18%) ▼|WMT108.51+1.36 (+1.27%) ▲|XOM168.43+2.44 (+1.47%) ▲|AAPL332.27+5.70 (+1.75%) ▲|ABBV257.12+2.12 (+0.83%) ▲|ABT104.20+2.20 (+2.15%) ▲|ACN192.45+8.59 (+4.67%) ▲|ADBE263.36+11.13 (+4.41%) ▲|AMAT421.84-34.65 (-7.59%) ▼|AMD484.37-31.76 (-6.15%) ▼|AMGN380.36+3.01 (+0.80%) ▲|AMT177.54-0.33 (-0.19%) ▼|AMZN254.39-2.40 (-0.93%) ▼|AVGO347.05-14.95 (-4.13%) ▼|AXP326.50+1.82 (+0.56%) ▲|BA209.55-0.78 (-0.37%) ▼|BAC62.35-0.34 (-0.53%) ▼|BKNG180.52+6.60 (+3.79%) ▲|BLK1,075.02-4.57 (-0.42%) ▼|BMY64.64+1.02 (+1.60%) ▲|BNY160.77-1.90 (-1.17%) ▼|BRK-B513.81+3.47 (+0.68%) ▲|C136.63-2.17 (-1.56%) ▼|CAT781.18-37.37 (-4.56%) ▼|CL88.32+1.54 (+1.77%) ▲|CMCSA25.34+0.14 (+0.56%) ▲|COF208.23-0.02 (-0.01%) ▼|COP139.12+1.75 (+1.27%) ▲|COST915.63+10.86 (+1.20%) ▲|CRM255.22+7.57 (+3.05%) ▲|CSCO110.03-2.10 (-1.87%) ▼|CVS95.72+1.05 (+1.11%) ▲|CVX216.90+2.86 (+1.34%) ▲|DE671.51-4.78 (-0.71%) ▼|DHR201.62+1.53 (+0.76%) ▲|DIS108.32+1.78 (+1.67%) ▲|DUK120.28+0.86 (+0.72%) ▲|EMR147.30-4.86 (-3.19%) ▼|FDX312.04+1.26 (+0.40%) ▲|GD357.16+1.25 (+0.35%) ▲|GE312.74-10.87 (-3.36%) ▼|GEV881.50-75.07 (-7.85%) ▼|GILD144.79+1.07 (+0.74%) ▲|GM86.44+0.82 (+0.96%) ▲|GOOG340.45+5.00 (+1.49%) ▲|GOOGL344.02+5.52 (+1.63%) ▲|GS1,008.54-20.57 (-2.00%) ▼|HD310.18+1.45 (+0.47%) ▲|HON199.13-3.23 (-1.60%) ▼|IBM246.04+2.80 (+1.15%) ▲|INTC95.43-7.51 (-7.30%) ▼|INTU339.11+17.54 (+5.45%) ▲|ISRG375.09+5.94 (+1.61%) ▲|JNJ269.57+3.95 (+1.49%) ▲|JPM353.51-2.77 (-0.78%) ▼|KO89.77+1.51 (+1.71%) ▲|LIN464.39-1.83 (-0.39%) ▼|LLY1,134.64+19.41 (+1.74%) ▲|LMT526.57+2.65 (+0.51%) ▲|LOW198.32+1.51 (+0.76%) ▲|LRCX274.44-23.79 (-7.98%) ▼|MA577.58+8.43 (+1.48%) ▲|MCD257.22+4.71 (+1.86%) ▲|MDLZ63.52+1.08 (+1.73%) ▲|MDT93.48+2.50 (+2.75%) ▲|META659.26+11.23 (+1.73%) ▲|MMM162.80-2.15 (-1.31%) ▼|MO70.96+1.99 (+2.89%) ▲|MRK145.72+1.78 (+1.24%) ▲|MS211.07-3.32 (-1.55%) ▼|MSFT496.53+0.90 (+0.18%) ▲|MU904.89-70.38 (-7.22%) ▼|NEE82.51+0.20 (+0.24%) ▲|NFLX79.77+2.37 (+3.06%) ▲|NKE37.12+0.30 (+0.82%) ▲|NOW140.94+8.41 (+6.34%) ▲|NVDA209.12-9.17 (-4.20%) ▼|ORCL141.79-8.36 (-5.57%) ▼|PEP138.52+2.20 (+1.61%) ▲|PFE27.95+0.26 (+0.94%) ▲|PG147.15+1.93 (+1.33%) ▲|PLTR167.08-0.15 (-0.09%) ▼|PM194.68+3.59 (+1.88%) ▲|QCOM176.50-5.48 (-3.01%) ▼|RTX195.71-1.97 (-1.00%) ▼|SBUX99.41+0.67 (+0.68%) ▲|SCHW107.49+0.24 (+0.22%) ▲|SO87.59+0.42 (+0.48%) ▲|SPG206.18+1.35 (+0.66%) ▲|T26.35+0.29 (+1.09%) ▲|TMO612.55+2.55 (+0.42%) ▲|TMUS185.25+2.92 (+1.60%) ▲|TSLA361.18-4.26 (-1.17%) ▼|TXN262.23-6.47 (-2.41%) ▼|UBER71.61-0.06 (-0.08%) ▼|UNH381.93+5.16 (+1.37%) ▲|UNP284.78+0.38 (+0.13%) ▲|UPS101.25+0.97 (+0.96%) ▲|USB62.98+0.14 (+0.22%) ▲|V375.96+5.51 (+1.49%) ▲|VZ51.13+0.52 (+1.03%) ▲|WFC90.13-0.16 (-0.18%) ▼|WMT108.51+1.36 (+1.27%) ▲|XOM168.43+2.44 (+1.47%) ▲|
21 C
New York
Monday, September 14, 2026

Tag: investor

newssourceFORcompanyinformationcontent1releasesmarket

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared...

SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA.

Prepayments (CK93) – Nykredit Realkredit A/S

To the Nasdaq Copenhagen

Teleste and VodafoneZiggo roll out Next-Gen DOCSIS 4.0 Broadband with Teleste’s 1.8 GHz Technology

Europe's first major 1.8 GHz deployment unlocks faster speeds and more reliable networks TURKU, Finland, July 14, 2025 /PRNewswire/ -- Teleste announces a landmark agreement...

NaaS Technology Inc. Announces Plan to Implement ADS Ratio Change

BEIJING, July 14, 2025 /PRNewswire/ -- NaaS Technology Inc. (Nasdaq: NAAS) ("NaaS" or the "Company"), the first U.S.-listed EV charging service company in China,...

Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform

Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&DFunds to accelerate Alzheimer's and immune disease...

OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025

PRESS RELEASE

Power Metallic Closes on Li-FT Power Land Acquisition

TORONTO, July 14, 2025 /PRNewswire/ - Power Metallic Mines Inc. (the "Company" or "Power Metallic") (TSXV: PNPN) (OTCBB: PNPNF) (Frankfurt: IVV) Power Metallic is pleased to...

Falcon Oil & Gas Ltd (“Falcon”) – Another Stellar IP60 Flow Test Result in the Beetaloo and 2025 Drilling Campaign Commences

Falcon Oil & Gas Ltd (“Falcon”)

NTG Nordic Transport Group A/S – H1 2025 Conference Call

NTG Nordic Transport Group A/S – H1 2025 Conference Call

OGN IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Organon & Co. Investors with Losses in Excess of $100K to Secure Counsel Before Important...

NEW YORK, July 13, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Organon & Co. (NYSE: OGN) between November 3, 2022 and April 30, 2025, both dates inclusive (the “Class Period”), of the important July 22, 2025 lead plaintiff deadline.

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies

DV DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages DoubleVerify Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before...

NEW YORK, July 13, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of DoubleVerify Holdings, Inc. (NYSE: DV) between November 10, 2023 and February 27, 2025, both dates inclusive (the “Class Period”), of the important July 21, 2025 lead plaintiff deadline.

IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, July 13, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or “the Company”) (NASDAQ: IOVA) and certain of its officers.

ROSEN, A TOP RANKED LAW FIRM, Encourages iRobot Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – IRBT

NEW YORK, July 13, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of iRobot Corporation (NASDAQ: IRBT) between January 29, 2024 and March 11, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 5, 2025.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInvestor

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers